Abstract
The advent of combination immune checkpoint inhibitors (cICI), specifically ipilimumab and nivolumab, has transformed the treatment landscape for metastatic renal cell carcinoma (mRCC), offering durable remissions and improved outcomes for intermediate- and poor-risk patients. However, intrinsic resistance remains a significant challenge, with 40-60% of patients failing to achieve meaningful responses. Here, we conducted a comprehensive, multi-omic analysis of systemic and tumor-associated immune responses in mRCC patients enrolled in a clinical trial (CA209-980, SAKK07/17, NCT03297593) testing a novel response-adapted cICI regimen. Our study aimed to identify immune correlates of response to cICI therapy.
High-dimensional mass cytometry and single-cell proteomic and bulk RNA sequencing of the tumor revealed an enrichment of Th17 CD4+ T cells in responders. These cells exhibited upregulated IL-21-driven pathways, IL-17 signaling, and inflammasome-associated processes, highlighting their central role in therapeutic efficacy.
Our integrative analysis underscores the importance of Th17 cells in mediating effective responses to cICI and provides a framework for developing predictive biomarkers and therapeutic strategies to overcome resistance. These findings highlight the translational potential of targeting Th17-centric pathways to enhance immunotherapy outcomes in mRCC and potentially other cancers. This work represents a significant step toward advancing personalized oncology through integrated immune profiling.
Competing Interest Statement
H.L. received travel grants and consultant fees from Bristol-Myers Squibb (BMS) and Merck, Sharp and Dohme (MSD). H.L. received research support from BMS, Novartis, GlycoEra and Palleon Pharmaceuticals. F.S. received travel grants from Roche, BMS, Celgene and research support from BMS and Takeda. C.K. declares ownership of Cell X Analytics LLC and contributions of reagents from MSD.
Clinical Trial
NCT03297593
Funding Statement
This work was supported and funded by Bristol-Myers Squibb, the Krebsliga Schweiz, and from the Schoenemakers-Mueller Foundation to H.L., ACS-IRG and DoD HT94252510707 to C.K., American Cancer Society RSG-24-1255025-01-IBCD and NCI R01 CA258882 to S.G. The work was supported in part by the NCI through the Cancer Bioinformatics Core, UPMC Hillman Cancer Center, University of Pittsburg (P30CA047904), and the Cell Evaluation & Therapy Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Medical University of South Carolina waived ethical approval for this work, as the study was determined to meet the criteria for Not Human Research (NHR; Pro00144924). This study involves the analysis of pre-existing, biobanked clinical samples obtained from a completed Phase II clinical trial (NCT03297593) conducted in Switzerland under the oversight of the Ethics Committee of Northwestern and Central Switzerland (EKNZ).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
